GlucoTrack, Inc. (NASDAQ:GCTK) surges 95% after LT-100 news, market eyes dilution impact
Shares of GlucoTrack jumped as Lōkahi Therapeutics proposed an easier pathway for LT-100. The fully owned subsidiary is seeking approval for a single subcutaneous injection rather than as many as 15 intradermal injections.
